title: Injectable neuromodulatory agents: botulinum toxin therapy.
abstract: Botulinum toxin therapy is a diverse treatment option for various dysfunctions of the lower urinary tract. The limited but growing clinical experience reveals that temporary chemodenervation with reduction or loss of neuronal activity at the target organ may be achieved with minimal risk. This highly favorable risk-benefit ratio in urology is derived from the clinical ability to treat an end-organ condition effectively with controllable site-specific delivery (eg, subcutaneous, intramuscular, or instillation) combined with high affinity for toxin uptake by the peripheral cholinergic nerves. Although many questions remain regarding the optimal use of this minimally invasive option for urologic applications, the opportunity for expanding indications will provide urologists with more options for addressing difficult challenges in voiding dysfunction.
authors.affiliation: Female Pelvic Medicine and Reconstructive Surgery, Glickman Urologic Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue A100, Cleveland, OH 44195, USA.
authors.forename: Tara L
authors.initials: TL
authors.lastname: Frenkl
authors.forename: Raymond R
authors.initials: RR
authors.lastname: Rackley
mesh_terms: D000818:Animals; D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use; D001743:Urinary Bladder / Q000187:drug effects; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy; D014555:Urination Disorders / Q000628:therapy*
chemical_list: D018726:Anti-Dyskinesia Agents; D009465:Neuromuscular Agents; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A